secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-07-16T23:59:59+00:00
Accession:  0001104659-24-080039
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Annovis Bio's transition to new crystal form of Buntanetap for trials
--------------------------------------------------------------------------------

- FDA approved transition to new crystalline form of Buntanetap for future clinical trials.
- Company filed composition of matter patent for new form and provisional patent for manufacturing process in June 2024.
- Comprehensive bridge studies in solvents and animals submitted to FDA.
- FDA clearance allows a small single-dose bioavailability study in humans as part of transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924080039/0001104659-24-080039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924080039/tm2419484d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-080039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer